Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

NOVEMBER 12, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. 11,141,404, titled “Formulations And Methods For Treating Acute Cannabinoid Overdose.” ” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

AUGUST 23, 2021

Oxford Cannabinoid Technologies Holdings plc. After confirmation of 6-months stability of tech-transfer batch, the work has been initiated, with preliminary data packages available by the second half of September, well within the proposed timelines. Pre-Close Trading Update; US OTC QB Market Application. &

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

Cannabis Law Report

NOVEMBER 12, 2021

THE Chairman of a recently-listed UK pharmaceutically-focused cannabis company has stood down after a breach of market rules. Neil Mahapatra is a co-founder of the Oxford Cannabinoid Technologies (OCT) which floated on the LSE in the May this year, he is also founder of UK venture capital business Kingsley Capital Partners (KCP).

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Project CBD

MAY 3, 2023

Goldstein will be leading the Medical Practicum at CannMed 2023 (May 15-17), where she will also be speaking about CBG and other minor cannabinoids during the main session. You have said that cannabigerol, or CBG, is one of your favorite cannabinoids. Is that because CBG is a precursor for the other plant cannabinoids?

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? There are many different medical cannabis products. .

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

The Cannigma

FEBRUARY 1, 2023

Even if a cannabinoid has shown promise on one cancer line, that doesn’t mean it will work for all cancers – even if it’s within the same organ system. Advocate for the rescheduling of cannabis to improve access to cannabis for research purposes, and scientific funding for novel cannabinoid-based cancer therapies.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

JULY 12, 2019

International Cannabinoid Cancer Research Institute (Draft 5). This paper seeks to answer why refined cannabinoids have more side effects than the natural cannabis product, as well as the possible etiology of said adverse reactions. Also discussed are other attempts at affecting the cannabinoid system from a singular standpoint.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Forward-looking statements.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. minor cannabinoids market size is expected to reach USD 26.2

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Project CBD

JANUARY 25, 2023

Statin medications deplete cannabinoid receptor function, according to a recent study by a team of distinguished Italian scientists. More troublesome, though, is that simvastatin alters genes involved in regulating cannabinoid receptors. Simvastatin also reduces cannabinoid receptor expression.

Cannabinoids 130

Cannabinoids Patients Data Extraction 130

Veriheal

JANUARY 26, 2023

Most commonly, pharmaceutical medication is prescribed to regulate moods. However, pharmaceutical medications can have side effects, and they may take longer to work for many patients. Thus, this groundbreaking study laid the foundation for understanding how cannabinoids can support mental health.

Treatment 98

Treatment Cannabinoids Conditions Pharmaceutical 98

United Patients Group

MAY 17, 2023

Some researchers believe that cannabinoids may help people with ASD manage anxiety and stress by increasing their ability to focus and pay attention. Cannabinoids have been shown to help people with autism manage anxiety and stress.

Sleep 105

Sleep Cannabinoids Patients CBD 105

Cannabis Law Report

FEBRUARY 2, 2022

– Flora’s research division, Flora Pharma, files USPTO provisional patent application on a cannabinoid-based formula. – Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA).

Cannabinoids 52

Cannabinoids Clinical Trials Events Cultivation 52

Cannabis Law Report

JANUARY 16, 2022

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.

Pharmaceutical 98

Pharmaceutical Research and Development Epilepsy Medicine 98

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales. 2 The seeds of C.

CBD 144

CBD Seed-To-Sale Food Access 144

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. How Do MMJ Restrictions Affect Patients and Doctors?

Access 98

Access Patients Chronic Pain Conditions 98

Cannabis Law Report

MARCH 29, 2022

to acquire Dutch medical cannabis company APIRx Pharmaceutical BV. Incannex was one of the first ASX-listed companies to make forays into cannabinoid and psychedelic therapeutic drugs (it was originally a direct-to-consumer dental business, which disrupted the dental space).

Pharmaceutical 52

Pharmaceutical Cannabinoids Data Policy 52

TheAnswerPage

DECEMBER 6, 2020

The findings of multiple randomized controlled trials (RCTs) indicate that cannabinoids effectively treat chronic pain. Do cannabinoids effectively treat the chronic pain associated with fibromyalgia?

Chronic Pain 52

Chronic Pain Cannabinoids Pharmaceutical Data 52

TheAnswerPage

JUNE 28, 2020

The findings of multiple RCTs indicate that cannabinoids effectively treat chronic pain. Do cannabinoids effectively treat the chronic pain associated with fibromyalgia? Note: The data from the 2019 study could not be used to extrapolate the long-term effects of cannabinoids on fibromyalgia-associated pain.).

Chronic Pain 52

Chronic Pain Cannabinoids Pharmaceutical Data 52

Cannabis Law Report

SEPTEMBER 14, 2021

A lack of consumer trust, transparency and scientific rigor has hampered the CBD and cannabinoid industry from reaching its growth potential for far too long”.

Extraction 52

Extraction Research and Development Clinical Trials CBD 52

The Cannigma

FEBRUARY 16, 2021

They require a process in which THC or other cannabinoid particles are reduced to nanoscopic size that allows them to then be mixed with water or other aqueous liquids. There is not extensive safety data available, however. The nanoemulsion method ALT uses is effective for all cannabinoids, not only THC, he said. Shutterstock).

Edibles 138

Edibles Digestion Tincture Cannabinoids 138

CannaMD

NOVEMBER 22, 2020

Unfortunately, most traditional pharmaceutical options are distinctly lacking due to side effects, as well as a bit of trepidation (although Botox, one current treatment option for migraines, has gained popularity). Patients used the app, Strainprint, which allowed data to be archived and studied.

Marijuana 116

Marijuana Treatment Patients Cannabinoids 116

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. The immediate next steps are to submit data for ethics committee review and approval whereupon acceptance, further details will be provided. “A

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

MARCH 22, 2020

A data firm is warning those infected with the novel coronoavirus to avoid consuming products that contain tetrahydrocannabinol (THC), the main psychoactive component of cannabis. Data CEO Julie Armstrong said her company knows the COVID-19 affects the population in a similar way to influenza. The brief survey can be taken here.

THC 59

THC Clinical Trials Data Consumption 59

Cannabis Law Report

JUNE 7, 2019

The use of pharmaceutical cannabinoid products in Singapore comes under strict frameworks and regulations and does not diminish the country’s zero-tolerance position against drugs, the Home Affairs and Health ministries have said. Cannabinoids are chemical compounds found in the cannabis plant. The Straits Times Reports.

Pharmaceutical 40

Pharmaceutical Cannabinoids Safety Data 40

The Cannigma

JUNE 14, 2021

We are allowed to cultivate, manufacture, research, analyze and distribute cannabis for scientifical, medical and pharmaceutical research. Second, it can change the content of both THC and potentially other cannabinoids and third, hopefully it will allow for testing different delivery methods.”. Shutterstock). A promise made years ago.

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Cannabis Law Report

JANUARY 14, 2022

3) Based on the available data, when there is a justified prospect that treatment success (curative or palliative) can be achieved with the medicine in question. This represents a major divestment of the company away from Europe and specifically from the isolates and pharmaceutical sector on the continent.

Pharmaceutical 52

Pharmaceutical Extraction Oil Patients 52

SpeedWeed

JULY 8, 2021

Clever Leaves , a cultivator, manufacturer and distributor listed on the Nasdaq, announced its entrance into Mexico last month with an active pharmaceutical ingredient (API) supply agreement with CBD Life, beginning with cannabidiol (CBD) isolate. A lot of these countries are just beginning their cannabinoid journey.”. Detwiler said.

Pharmaceutical 52

Pharmaceutical Cannabinoids Supply Chain Cultivation 52

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. Additionally, there are misleading practices of “p-hacking” where researchers can manipulate data through different statistical tests (thanks to modern computer programs) looking for statistically significant findings.

Research and Development 112

Research and Development Data THC Clinical Trials 112

The Cannigma

JUNE 15, 2021

Cannabidiol (CBD) belongs to a class of molecules called cannabinoids , which are produced almost exclusively in cannabis — hence the name. The two cannabinoids can also cause very different effects in other ways. CBD is also often compared to CBG (cannabigerol) , another increasingly popular cannabinoid. CBD vs CBDA.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Canna Law Blog

FEBRUARY 21, 2020

The EFSA guidance on cannabinoids strongly echoes the U.S. Although the UK recently severed its ties with the European Union, the FSA has opted to align its policy with that of the European Food Safety Authority (“ EFSA ”).

Food 102

Food CBD Legalization Hemp 102

Veriheal

JANUARY 4, 2021

In adults with chronic pain, what are the harms of cannabinoids? In adults with chronic pain, what are the benefits of cannabinoids? Cannabis is a plant loaded with cannabinoids like THC , CBN , CBG , CBD , and others. Medicinal cannabinoid therapies are saving and changing lives for people across America and around the world.

Chronic Pain 104

Chronic Pain Therapy Cannabinoids Treatment 104

Cannabis Law Report

FEBRUARY 15, 2019

The Singapore Online Citizen reports… Law & Home Affairs Minister K Shanmugam says that pharmaceutical companies are hiding their intentions behind a smokescreen when it comes to cannabis. On the other hand, they found that are some medicine with cannabinoid products that are scientifically researched and medically approved.

Medicine 45

Medicine Pharmaceutical Law Cannabinoids 45

Cannabis Law Report

SEPTEMBER 21, 2021

.–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has published its latest paper in the medical journal Frontiers in Psychiatry , examining the benefits of medicinal cannabis products for individuals with anxiety and depression. Justin Strickland, Instructor at Johns Hopkins University.

CBD 52

CBD Data Therapy Sleep 52

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov. About INM-755.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40